Vertex Pharma stock pre-market at EUR 467.88: biotech company

Published on 10/26/2026 at 07:49 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The biotechnology group develops and commercializes medicines for serious diseases. At Lang & Schwarz the stock trades pre-market at EUR 467.88 on October 26, 2026.

Business model and morning price

Vertex Pharmaceuticals develops and commercializes medicines for serious diseases.
The relevant home-market benchmark for October 26, 2026 is the S&P 500.
Vertex Pharma stock trades pre-market at EUR 467.88 at 7:48 a.m. CET at Lang & Schwarz on October 26, 2026.

Extreme Nahaufnahme von Pharmakapseln und Tabletten auf glänzender Glasoberfläche — Vertex Pharma US92532F1003 zeigt eine Makroaufnahme von Pharma-Kapseln und Tabletten mit feinen Wassertropfen, Illustration mit AI erstellt.

Vertex Pharmaceuticals develops and commercializes medicines for serious diseases, according to MarketBeat. Vertex Pharma stock trades pre-market at EUR 467.88 at 7:48 a.m. CET at Lang & Schwarz on October 26, 2026.

Before the Xetra open

The early indication is available ahead of the regular Xetra session. The continuously updated real-time quote of Vertex Pharma stock shows the further course from the Xetra open at 9:00 a.m. CET.

Company and market context

Vertex Pharmaceuticals earns revenue by developing and selling medicines, with its portfolio including treatments for cystic fibrosis, according to MarketBeat. The relevant home-market benchmark for October 26, 2026 is the S&P 500.

Market context: Market report S&P 500.

More news and analysis on Vertex Pharma stock